The global human microbiome market size was valued at USD 595.45 million in 2021 and is estimated to expand at a substantial CAGR during the forecast period, 2021 – 2028. The growth of the market is attributed to increasing research studies in microbiome.
Human microbiome includes all microbiotas including bacteria, fungi, viruses, archaea, and protists that live both inside human tissues and out of the human body. They reside on the skin, lung, gastrointestinal tract, mammary gland, seminal fluid, saliva, uterus, and others. Understand the traits of human microbiome in an individual is essential for various health-related development, nutrition, and immunity system. When numbers of these microbiome alter, it leads to several diseases such as diabetes, arthritis, gastrointestinal disorder, and other disorders. According to the Centers for Disease Control and Prevention (CDC), approximately 2.8 million antibiotic-resistant infections occur every year in the US. Several studies, research, and projects are being vastly conducted globally to analyze microbiome’s impact on human bodies. For example, the Million Microbiome of Humans Project (MMHP) was initiated at 14th International Conference on Genomics (ICG-14) in 2019.
Meanwhile, observing the causal link between microbiome and diseases, it has become more evident with COVID-19 situation than it was before. Several studies show that lung microbiome plays a crucial role in generating immune response against viral attacks, affecting the outcome of COVID-19. During pandemic, research organizations and companies had collaborated with governments to develop therapeutics to prevent future health crisis by increasing research studies on lung microbiome’s impact on the disease’s severity and susceptibility.
Market Trends, Drivers, Restraints, and Opportunities:
- Wide prevalence of lifestyle-related diseases such as diabetes or other chronic illness as well as rising geriatric population globally are the key factors propelling the market.
- Increasing governments’ initiatives and programs to foster various healthcare research on microbiome and its related field is expected to drive the market growth during the forecast period.
- Rapid development of advanced technology for diagnosis and therapeutics of illness such as obesity, gastrointestinal disorder, and autoimmune disorder present another key driver of the market.
- Lack of comprehensive government policies and high capital requirement for research programs are main hurdles, which are expected to restrain the market growth during the forecast period.
- Ongoing massive research on microbiome and immune response study to fight chronic diseases is offering lucrative growth opportunities of the market.
Scope of the Report
The report on the global human microbiome market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Human Microbiome Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018–2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Applications (Diagnostics and Therapeutics), Diseases (Diabetes, Obesity, Gastrointestinal Disorder, Autoimmune Disorder, Central Nervous System Disorder, and Others), and Products (Prebiotics, Probiotics, Symbiotic, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Yakult Honsha Co. Ltd; Seres Therapeutics; DuPont; Synthetic Biologics Inc.; and Second Genome.
|
Market Segment Insights:
Therapeutic segment to account for a large market share
Based on applications, the global human microbiome market is divided in diagnostics and therapeutics. The therapeutic segment is expected to account for a large market share owing to wide range of treatment application for disorders such as inflammatory bowel disease, difficile infection, Crohn’s disease, diabetes, and other diseases. During the COVID-19 pandemic, therapeutic products are widely used for various applications such as treatment of corona patients, which further boosts the segment.
Obesity segment to hold a large share in the market
Based on diseases, the market is segmented in diabetes, obesity, gastrointestinal disorder, autoimmune disorder, central nervous system disorder, and others. The obesity segment is expected to hold a large share of the market during the forecast period owing to wide prevalence of excessive-weight problems especially in the developed countries. On the other hand, the diabetes segment is expected to grow rapidly during the targeted period due to increasing cases of diabetes worldwide and massive R&D activities to study the relationship between microbiome and its impact on diabetes.
Increasing awareness to drive probiotics segment
On the basis of products, the global human microbiome market is divided in prebiotics, probiotics, symbiotic, and others. The probiotics segment is projected to register a high CAGR during the forecast period owing to increasing health awareness about positive effects of probiotics food and beverages among consumers. Moreover, the wide availability of probiotics food and beverages products is likely to boost the segment in the coming years.
North America to dominate the market
In terms of regions, the global human microbiome market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is projected to dominate the market during the forecast period due to wide prevalence of chronic disorders such as autoimmune disorders and lifestyle-related diseases in the region. Moreover, several governments’ initiatives towards the robust research related to microbiome and other chronic illness present another key factor propelling the regional market. For instance, the Government of Canada announced in 2019 that it had made an investment worth USD 18 million for microbiome studies and research.
Segments
The global human microbiome market has been segmented on the basis of
Applications
Diseases
- Diabetes
- Obesity
- Gastrointestinal Disorder
- Autoimmune Disorder
- Central Nervous System Disorder
- Others
Products
- Prebiotics
- Probiotics
- Symbiotic
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Yakult Honsha Co. Ltd
- Seres Therapeutics
- DuPont
- Synthetic Biologics Inc.
- Second Genome
Competitive Landscape
Key players competing in the global human microbiome market are Yakult Honsha Co. Ltd; Seres Therapeutics; DuPont; Synthetic Biologics Inc.; and Second Genome. These players use strategies such as mergers, acquisitions, expansions, partnerships, and product launches to increase their customer base and strengthen their hold on the market. For example, in June 2021, NovoBiome announced the development of a research and discovery platform, NovoSift, which primarily investigates the symbiotic relationship between microbiota and human intestine.
Request For Customization
Enquiry Before Buying
Speak With Analyst
